- Home
- EHGO vs ENTX Comparison
EHGO vs ENTX Comparison
Compare EHGO & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EHGO
- ENTX
- Stock Information
- Founded
- EHGO 2015
- ENTX 2010
- Country
- EHGO China
- ENTX Israel
- Employees
- EHGO N/A
- ENTX N/A
- Industry
- EHGO
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EHGO
- ENTX Health Care
- Exchange
- EHGO NYSE
- ENTX Nasdaq
- Market Cap
- EHGO N/A
- ENTX 104.0M
- IPO Year
- EHGO 2024
- ENTX 2018
- Fundamental
- Price
- EHGO $0.88
- ENTX $1.83
- Analyst Decision
- EHGO
- ENTX Strong Buy
- Analyst Count
- EHGO 0
- ENTX 1
- Target Price
- EHGO N/A
- ENTX $10.00
- AVG Volume (30 Days)
- EHGO 3.1M
- ENTX 32.7K
- Earning Date
- EHGO 07-15-2025
- ENTX 08-08-2025
- Dividend Yield
- EHGO N/A
- ENTX N/A
- EPS Growth
- EHGO N/A
- ENTX N/A
- EPS
- EHGO N/A
- ENTX N/A
- Revenue
- EHGO $15,393,105.00
- ENTX $223,000.00
- Revenue This Year
- EHGO N/A
- ENTX N/A
- Revenue Next Year
- EHGO N/A
- ENTX N/A
- P/E Ratio
- EHGO N/A
- ENTX N/A
- Revenue Growth
- EHGO N/A
- ENTX N/A
- 52 Week Low
- EHGO $0.72
- ENTX $1.41
- 52 Week High
- EHGO $5.50
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- EHGO N/A
- ENTX 39.81
- Support Level
- EHGO N/A
- ENTX $1.84
- Resistance Level
- EHGO N/A
- ENTX $2.02
- Average True Range (ATR)
- EHGO 0.00
- ENTX 0.13
- MACD
- EHGO 0.00
- ENTX -0.02
- Stochastic Oscillator
- EHGO 0.00
- ENTX 7.89
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.